This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Biotech Stock Mailbag: Soligenix

BOSTON ( TheStreet) -- Thanks for returning to the Biotech Stock Mailbag.

Let's kick things off with an email from Dennis W., who asks:

" I would love you to write about Soligenix (SNGX.OB), as it is in a phase III trial for graft-versus-host disease (GVHD). Since the Osiris Therapeutics (OSIR - Get Report) trial imploded, Soligenix has the only treatment on the horizon for this disease. At 25 cents per share, this stock seems very undervalued. Thanks for all you do to keep small investors like me informed!"


When I last heard from Soligenix, it was May 2007 and the small drug company was known as DOR Biopharma. The vice chairman at the time, Steve Kanzer, was being physically restrained and forcibly removed from an FDA advisory panel meeting that voted against approving Soligenix's GVHD drug OrBec. (Click here and scroll to photo No. 4 to see Kanzer's terrible, horrible, no good, very bad day.)

In October 2007, the FDA followed through, as expected, and refused to approve OrBec. Over the next two years, DOR worked with the FDA to agree on the design for a new, confirmatory phase III study of OrBec in GVHD patients, which if successful, could be used to re-file the drug with the FDA.

That study began last October; top-line results are expected in the first half of 2011.

OrBec carries the stigma of a drug scorned once by the FDA, but the previous phase III data weren't terrible. OrBec demonstrated a positive effect on the gastrointestinal (GI) manifestations of GVHD -- and OrBec patients lived longer -- but the study failed to meet its primary endpoint mainly because of a bad study design. For this reason, the FDA wanted the company to conduct a confirmatory study.

The primary endpoint of the new study is treatment failure at study day 80, which was one of the positive, statistically significant secondary endpoints in the old study. The new study is also enrolling more patients and is better powered statistically than the old study.

1 of 7

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
CTIC $1.96 0.00%
IMMU $4.09 0.00%
KERX $11.41 0.00%
OSIR $16.33 0.00%
AAPL $130.28 0.00%


DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs